BERLIN (EGMN) - Induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil offers a sustained survival advantage in locally advanced squamous cell carcinoma of the head and neck, according to the most recent results of a key clinical trial.At a minimum 5 years' follow-up in 88% of the 501 participants in the phase III TAX 324 trial, 52% of those treated with the combined regimen of docetaxel (Taxotere), cisplatin, and 5-FU (the TPF regimen) were alive vs. 42% of those who were treated with...